BioNTech CEO Says Possible to Adapt Vaccine Quickly for Omicron

FRANKFURT — Germany’s BioNTech should be able to adapt its coronavirus vaccine relatively quickly in response to the emergence of the Omicron variant, its CEO Ugur Sahin told the Reuters Next conference on Friday. Read More